Report overview
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer
This report contains market size and forecasts of Drugs Based on CAR T-cell in Global, including the following market information:
Global Drugs Based on CAR T-cell Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Drugs Based on CAR T-cell market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
CD19-targeted Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Drugs Based on CAR T-cell include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics and FOSUNKite, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drugs Based on CAR T-cell companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs Based on CAR T-cell Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Drugs Based on CAR T-cell Market Segment Percentages, by Type, 2022 (%)
CD19-targeted
BCMA-targeted
Global Drugs Based on CAR T-cell Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Drugs Based on CAR T-cell Market Segment Percentages, by Application, 2022 (%)
Lymphoma
Multiple Myeloma
Global Drugs Based on CAR T-cell Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Drugs Based on CAR T-cell Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs Based on CAR T-cell revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drugs Based on CAR T-cell revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
